Kornimate/medical-research-clean huggingface dataset:
the apos system: effects on gait, mobility and qol in patients with parkinson's disease

Conditions: Idiopathic Parkinson's Disease

Summary: the purpose of this study is to evaluate the benefits of a biomechanical wedge system - the apos system, for improving the stability of gait, mobility and quality of life in parkinson's disease patients.

recently, a biomechanical wedge system was developed for gait and balance training among patients suffering from gait disorders. the apos system (apos medical \& sports technologies ltd, hertzeliya, israel) applies special semispherical shoes, with individually adjusted implants, to improve age- and disease-related loss in muscle strength and neuromuscular control. the semispherical rubber devices that are placed on the soles of the shoes at the hind-foot and mid-foot can be moved medially, laterally, forwards and backwards. the system can be individually adjusted in order to optimally balance loading and re-train postural control during gait. an additional advantage of this treatment approach is the extraordinary compliance. the system is easily adjusted, maintained, and allows safe gait training. after randomization, all subjects will be fitted with the apos system, these shoes alter the dynamic balance during all gait cycle phases, adjusting the center of gravity and training postural control. the precise location of the two wedges is adjusted individually by expert trainers using standardized protocols. subjects in the intervention group will receive a proper wedge; subjects in the sham group will receive an almost flat wedge that lacks the proper biomechanical characteristics. however, both shoes and wedges will look similar. all subjects will be instructed to start gradually, with a goal of reaching 30 minutes of in-home walking while wearing the special training shoes. as an extra pre-caution, all subjects will be asked to walk with the shoes only in the presence of a caregiver, spouse or other family member during the first month. before moving to more independent training, subjects will be checked for safety.

Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease * stage 2-3 hoehn \& yahr exclusion criteria: * peripheral neuropathic pain * dementia * severe orthopaedic condition * c.v.a * hearing or vision loss * usage of walking aid

Keywords: parkinson's disease gait disturbances mobility quality of life
efficacy of pethidine, ketorolac and xylocaine gel as analgesics for pain control in shockwave lithotripsy

Conditions: Analgesia; Urolithiasis

Summary: a randomised prospective trial comparing the efficacy of pethidine, ketorolac, and xylocaine gel as analgesics for pain control in shockwave lithotripsy.

pain perception during shockwave lithotripsy (swl) is affected by patient-related factors like age, gender, and body habitus moreover, young female patients, anxious and depressed patients or thin patients experience more pain during swl. several physical variables influencing treatment-related pain have been identified: the type of the shockwave source, size, and site of stone burden, peak pressure of the shockwaves, diameter of the focal zone, and size of the aperture of the shockwave source reflecting the area of shockwave entry at the skin. pain relief during swl is vital, not only to maintain patient comfort and satisfaction, but also to facilitate stone imaging and targeting by reducing patients' movements during successive shock wave impacts. reduced patient movement enables increase fragmentation efficiency and reduce the risk of procedure-related morbidity. so, a relaxed, cooperative patient during treatment is paramount in maintaining stone targeting for optimal fragmentation. across 21 centers in the united kingdom (uk), 17 distinct analgesia regimens were reported in swl analgesia practice. in 2016 european association of urology (eua) guidelines for swl pain control stated that pain control during swl is necessary to limit pain induced movements and excessive respiratory excursions, however no recommendation for proper analgesia in contrast to clear recommendation for pain relief in patients with an acute stone episode. the investigators will try in this trial to identify the best efficacious type of analgesia for patient during swl in this study.

Eligibility criteria:
inclusion criteria: * patients with renal and upper ureteral stones amenable to swl. exclusion criteria: * allergy to pethidine. * allergy to ketorolac. * allergy to xylocaine gel. * american society of anesthesiologists score ≥ 3 (asa iii or more). * pregnancy. * patients with a pacemaker. * bleeding diatheses. * uncontrolled urinary tract infection (uti). * severe obesity which prevent targeting of the stone. * body mass indexbmi (40 or more) * arterial aneurysm in the vicinity of the stone. * anatomical obstruction distal to the stone.

Keywords: shock wave lithotripsy ketorolac xylocaine gel pethidine
to verify the efficacy of z-338 in subjects with functional dyspepsia

Conditions: Functional Dyspepsia

Summary: the purpose of this study is to verify the superior efficacy of z-338 to placebo in subjects with functional dyspepsia, focusing on the assessment of subjective symptoms.


Eligibility criteria:
inclusion criteria: * subjects showing at least one of the 4 symptoms (upper abdominal pain, upper abdominal discomfort, epigastric pain, epigastric burning) for at least 6 months before obtaining informed consent * subjects showing two or more of the following symptoms: upper abdominal pain, upper abdominal discomfort, post-prandial fullness, upper abdominal bloating, early satiety, nausea, vomiting and/or excessive belching for at least 3 months (one of them should be post-prandial fullness or early satiation) * bothersome symptoms should be post-prandial fullness, upper abdominal bloating or early satiety at the time of obtaining informed consent exclusion criteria: * subjects with structural disease that is likely to explain the symptom (e.g., gerd, erosion, ulcer, hiatal hernia, bleeding, malignancy or barrett's esophagus) confirmed by upper endoscopy at the obtaining informed consent * subjects have heartburn in last 12 weeks before obtaining informed consent * subjects with irritable bowel disease (ibs) * subjects with diabetes mellitus requiring treatment * subjects with serious anxiety disorder * subjects with depression and/or sleep disorder * subjects with biliary tract disease and/or pancreatitis (including chronic pancreatitis)

Keywords: acotiamide
dietary intervention and vascular function

Conditions: Cardiovascular Disease

Summary: it is well established that diet plays an important role in both the development and progression of heart disease. different types of dietary fat have varying effects on heart disease risk factors. the elasticity of an individual's blood vessels is strongly associated with heart disease risk and recent evidence suggests that dietary manipulation may influence elasticity of the blood vessels with dietary fat (including saturated, monounsaturated and polyunsaturated fatty acids) as a potentially important modulator. substantial evidence exists on the effects of monounsaturated fats (type of fatty acids mainly found in olive and rapeseed oil), n-6 polyunsaturated fats (type of polyunsaturated fatty acids found in vegetable oils) and saturated fat (found mainly in animal derived products) on lipid levels. however, the influence of these dietary fats on the elasticity of blood vessels remains unclear.the main purpose of the divas study is to determine the effects of the substitution of saturated fats with either n-6 polyunsaturated or monounsaturated fats on blood vessel elasticity and to determine the effects of these different dietary fats on other risk factors for heart disease including lipoproteins and inflammatory biomarkers.


Eligibility criteria:
inclusion criteria: adults should have a relative risk (rr) of \> 1.5 of developing cardiovascular disease (cvd) based on presenting with at least one recognised risk factor for cvd: * total cholesterol (tc) \> 6.0 mmol/l * hdl cholesterol (hdlc) ≤ 1.0 mmol/l male, ≤ 1.3 mmol/l female * glucose ≥ 6 mmol/l * stage 1 hypertension or above i.e. a systolic bp ≥ 140 mmhg, diastolic bp ≥ 90 mmhg * bmi 28-35 kg/m2 * waist \>102 cm male or \> 84 cm female * adults with a first degree relative with either a history of premature cvd - age of onset younger than 55 y in fathers, sons or brothers or younger than 65 y in mothers, daughters or sisters, or type 2 diabetes. exclusion criteria: * having suffered a myocardial infarction/stroke in the past 12 months * diabetic (diagnosed or fasting glucose \> 7 mmol/l) or suffer from other endocrine disorders * suffering from renal or bowel disease or have a history of choleostatic liver or pancreatitis * on drug treatment for hyperlipidaemia, hypertension, inflammation or hypercoagulation * no history of alcohol abuse * planning or on a weight reducing regime * taking any fish oil, fatty acid or vitamin and mineral supplements * pregnant, lactating or planning a pregnancy * smokers

Keywords: fatty acids cardiovascular disease vascular function microparticles
hyperintense: midlife hypertension and the brain

Conditions: Hypertension; Small Vessel Cerebrovascular Disease

Summary: cerebral small vessel disease (svd) describes a set of pathologies affecting the smallest blood vessels in the brain. svd contributes to up to a fifth of ischemic and hemorrhagic strokes en is the main vascular cause of dementia. on mri, svd is marked by different types of lesions, including white matter abnormalities, and small infarcts and hemorrhages. recent studies indicate that svd develops slowly over the years, starting presumably decades before the typical mri lesions become apparent. high blood pressure plays an important role in the development of svd mri lesions. however, it remains unclear exactly how hypertension leads to vascular pathology. to gain more insight into how hypertension leads to svd it is important to study mechanisms in individuals (largely) free of svd, that is before midlife. therefore, the investigators aim to examine abnormalities in brain (micro) structure and vascular function in young patients with hypertension. furthermore, the investigators aim to determine the effects of blood pressure increase and subsequent blood pressure reduction during a period of withdrawal and restart of blood pressure lowering drugs on brain (micro)structure and vascular function.


Eligibility criteria:
study 1: cross-sectional study inclusion criteria: * age 18-40 years * blood pressure above 140/90 mmhg, measured within three months prior to study participation exclusion criteria: * pre-existing cerebrovascular disease * pregnancy * contraindications for 3 t mri * renal function egfr below 30 ml/min (for dynamic contrast enhanced \[dce\]-mri * major risk factors for acute ischemic stroke other than svd according to the toast criteria, including, but not limited to, large-artery atherosclerosis, cardioembolism and vasculitis based on medical history and ultrasound of the carotids collected at baseline or any chronic disease that could lead to brain lesions mimicking svd * major (neurological/psychiatric) disease (e.g. multiple sclerosis) * not able to give informed consent study 2: longitudinal study inclusion criteria: * age 18-55 years * undergoing diagnostic routine of temporary antihypertensive withdrawal for biochemical analysis as part of clinical work-up exclusion criteria: * pre-existing cerebrovascular disease * pregnancy * contraindications for 3 t mri * renal function egfr below 30 ml/min (for dynamic contrast enhanced \[dce\]-mri * major risk factors for acute ischemic stroke other than svd according to the toast criteria,22 including, but not limited to, large-artery atherosclerosis, cardioembolism and vasculitis based on medical history and ultrasound of the carotids collected at baseline or any chronic disease that could lead to brain lesions mimicking svd * major (neurological/psychiatric) disease (e.g. multiple sclerosis) * not able to give informed consent
computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts in anterior atrophic maxilla: a case series

Conditions: Ridge Augmentation

Summary: 10 patients having deficient anterior maxilla will be recruited and a preoperative cbct will be done to evaluate the vertical and horizontal dimensions of the intended alveolar ridge. pre-operative manufacturing of the digital surgical guides performed for harvesting of the chin cortical bone struts from the symphysial area in the donor site and for placement of the grafted cortical bone struts and the implant in the recipient site. intra operatively the donor site (chin) will be prepared to harvest autogenous bone from the chin aided by the patient's prefabricated bone harvesting guide. the recipient site (maxillary anterior defect) will be prepared to receive the chin grafts. grafts will be screwed in position and implants will be screwed in its preparation until it gains primary stability from basal bone, using the prefabricated bone fixation-implant placement guide. any gaps will be filled with autogenous bone particulates from the chin. a healing tie base abutment will be screwed into the implant through the third cortex. primary stability will be assessed using osstell device. an immediate postoperative cbct will be done and superimposed on the preoperative cbct to measure accuracy of plan transfer to make sure the planning was followed accurately. follow up after 6 months and cbct will be done for bone formation and density assessment and implant exposure for implant stability measurement-using osstell and removal healing abutment and consecutive prosthetic loading.


Eligibility criteria:
inclusion criteria: * patients with single or multiple missing maxillary anterior teeth with vertically and horizontally defective ridges having adequate soft tissue ample. * patients who gave their consent for this trial. * males and females will be included. exclusion criteria: * patients on bisphosphonates or drugs altering bone metabolism, within 2 months before initiating the study. * subjected to irradiation in the head and neck area less than 1 year before implantation. * patients allergic to drugs used in the study. * patients having a history of a major medical condition (asa 3,4) * untreated periodontitis. * poor oral hygiene and motivation. * uncontrolled diabetes. * pregnant or nursing. * substance abuse. * psychiatric problems or unrealistic expectations. * severe bruxism or clenching. * immunosuppressed or immunocompromised patients. * treated or under treatment with intravenous amino-bisphosphonates. * active infection or severe inflammation in the area intended for implant placement. * unable to open mouth sufficiently to accommodate the surgical tooling. * patients participating in other studies, if the present protocol could not be properly followed. * referred only for implant placement or unable to attend a 5-year follow-up.
effectiveness of oral hygiene instructions given by ai-generated videos vs. traditional approach in periodontal patients

Conditions: Gingivitis; Periodontitis

Summary: patients attending dubai dental hospital and requiring nonsurgical periodontal therapy will be invited to take part in the study. potential participants will be screened and selected based on the inclusion and exclusion criteria the aims of the randomized controlled trial are: 1. to compare the influence of ai-generated instructions versus traditional methods in improving the oral hygiene habits of patients diagnosed with periodontitis 2. to assess the time and cost effectiveness of applying ai-generated oral hygiene instructions in daily practice 3. to evaluate the level of patients' engagement, preference, and satisfaction with technology-based interactions vs. patient-doctor interaction research design * prospective, in which participants will be recruited and then followed up throughout a specified period of time. * randomized, parallel designed, concurrent controlled trial with participants randomly allocated to either control or test groups. the study will involve two stages, 1) digital avatar creation and 2) clinical component. the participants will be randomly allocated to two equal sized groups (30 per group) using computer-generated numbers: control group (c): standard oral hygiene instructions will be given verbally by the periodontics resident. test group (t): avatar-based group will receive oral hygiene instructions from a digital avatar of their choice.


Eligibility criteria:
inclusion criteria: aged 18 or over. diagnosed with gingivitis or generalized periodontitis, stage i-iv and grade a-c. good compliance and commitment to attend follow-up review appointments. willing to provide informed consent. exclusion criteria: received periodontal treatment in the last 12 months. received systemic anti-inflammatory or antibiotic treatment in the last 3 months. history of malignancy, radiotherapy, or chemotherapy. pregnant or lactating women. use of medication known to cause gingival overgrowth. participants that require prophylactic antibiotic.
validation of a scale of well-being assessment (siwa) in patients with alzheimer's disease or a related disease.

Conditions: Well-Being

Summary: current scales are not suited to a direct measure for the elderly with cognitive disorders and are difficult to handle for the care teams. in this context, a visual analog scale was created to answer a single question "how are you feeling now, immediately?" with the help of pictograms. this study aims to assess the validity and reliability of the scale of well-being assessment (siwa) (in french : echelle d'evaluation instantanée du bien-etre (evibe)) in people with alzheimer's disease or a related disease.


Eligibility criteria:
inclusion criteria: * enrolled patients must have given themselves, or through a trusted person referred to the article l. 1111-6 of the code of public health, failing thereof, by the family, or, a person maintaining close and stable ties. for adults under guardianship, permission must be given by the legal representative of the person. the research will benefit from the backing of persons protection committee (ppc) prior to its implementation. * patient living in one of the nursing home or hospital services in the project; * patient with alzheimer's or a related disease exclusion criteria: * severe, progressive or unstable pathology, which may interfere with the evaluation variables; * deafness or blindness may compromise patient assessment

Keywords: dementia alzheimer well-being
open-label study of imgn779 in adult patients with relapsed/refractory cd33-positive acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: this is an open label, multicenter phase 1 study to determine the mtd, dosing schedule and rp2d of imgn779 when administered as mono-therapy to adult aml patients with cd33 -positive disease.

in the dose escalation phase, patients will be assigned to one of three schedules. the mtd for all schedules will be determined from the assessment of dose limiting toxicities (dlts). the dose expansion phase will consist of one cohort based on patients response to prior therapy according to the mtd selected.

Eligibility criteria:
inclusion criteria: * dose escalation: patients with relapsed or refractory aml * dose expansion: patients with relapsed aml or patients who refuse, or are not suitable candidates for induction therapy exclusion criteria: * dose escalation: acute promyelocytic leukemia * any concurrent anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational agents (with the exception of hydroxyurea or leukapheresis for control of hyperleukocytosis) within 14 days or five half-lives of drugs, whichever is shorter, prior to cycle 1 day 1 * aml patients with known, active leptomeningeal/central nervous system (cns) involvement * prior treatment with imgn779 * women who are pregnant or breast feeding

Keywords: acute myeloid leukemia aml imgn779 immunogen phase 1 relapsed refractory cd33 dose escalation dose expansion
a phase i/ii clinical trial of lbl-033 in the treatment of advanced malignant tumors

Conditions: Advanced Malignant Tumors

Summary: this trial is an open and multicenter phase i/ii clinical study, which aims to evaluate the safety, tolerability, pk characteristics, immunogenicity, and effectiveness.

this is an open, multicenter phase i/ii clinical trial of lbl-033 in the treatment of patients with advanced malignant tumors，which aims to evaluate the safety, tolerability, pk characteristics, immunogenicity, and effectiveness. the trial is divided into 2 parts: phase 1 and phase 2 phase i study: dose-escalation and pk expansion.the pk expansion study will be judged on the basis of dose escalation data. phase ii study: dose expansion included 4 cohorts that required patients with muc16-positive malignancies.blood samples will be collected from all subjects in this trial. phase i and phase ii studies are expected to recruit 113-468 patients

Eligibility criteria:
inclusion criteria: 1. agree to follow the experimental treatment plan and visit plan, join the group voluntarily, and sign a written informed consent form; 2. age ≥ 18 years old when signing the informed consent form; 3. the eastern cooperative oncology group's physical status scoring standard (ecog) is 0\~1; 4. the expected survival time is at least 12 weeks; 5. according to the evaluation of recist 1.1 standard, the subjects enrolled have at least one measurable target lesion; 6. subject has adequate organ and bone marrow function，conforming to laboratory test results: 7. males with fertility and females of childbearing age are willing to take effective contraceptive measures from the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception sets，etc）; women of childbearing age include pre-menopausal women and women within 2 years after menopause. women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered. exclusion criteria: 1. have received other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time; 2. patients with active infection and currently requiring intravenous anti-infective treatment； 3. those who have clinically uncontrollable pleural effusion, pericardial effusion , requiring repeated drainage or medical intervention; 4. the patient has a medical history of immunodeficiency, including hiv antibody positive； 5. women during pregnancy or lactation; 6. the investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.